Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
作者信息
Grenader Tal, Rosenbaum Eli, Zilber Sofia, Bogot Naama, Shavit Linda
机构信息
Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
出版信息
Clin Genitourin Cancer. 2013 Jun;11(2):201-3. doi: 10.1016/j.clgc.2012.11.005. Epub 2012 Dec 23.
PMID:23266054
Abstract
摘要
相似文献
1
Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Clin Genitourin Cancer. 2013 Jun;11(2):201-3. doi: 10.1016/j.clgc.2012.11.005. Epub 2012 Dec 23.
2
Sorafenib in renal cell carcinoma.
Pak J Pharm Sci. 2014 Jan;27(1):203-8.
3
c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Clin Genitourin Cancer. 2013 Jun;11(2):134-40. doi: 10.1016/j.clgc.2012.08.007. Epub 2012 Oct 9.
4
Third-line dovitinib in metastatic renal cell carcinoma.
Lancet Oncol. 2014 Mar;15(3):245-6. doi: 10.1016/S1470-2045(14)70082-8. Epub 2014 Feb 17.
5
Effects of antiangiogenic therapy.
J Vasc Interv Radiol. 2012 Nov;23(11):1503. doi: 10.1016/j.jvir.2012.08.002.
6
Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
Ther Apher Dial. 2017 Aug;21(4):414-416. doi: 10.1111/1744-9987.12544. Epub 2017 Jun 8.
7
Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Int J Urol. 2012 Nov;19(11):1041-2. doi: 10.1111/j.1442-2042.2012.03099.x. Epub 2012 Jul 13.
8
[Drug now immediately available in Germany].
Aktuelle Urol. 2006 Sep;37(5 Suppl):18-9.
9
Sorafenib induced eruptive melanocytic lesions.
Dermatol Online J. 2013 May 15;19(5):18184.
10
New options for second-line therapy of advanced renal cancer.
Lancet Oncol. 2013 May;14(6):450-1. doi: 10.1016/S1470-2045(13)70119-0. Epub 2013 Apr 16.
Zotero 插件